Becker's Healthcare November 20, 2024
Mackenzie Bean

The FDA granted accelerated approved to the first gene therapy directly administered into the brain on Nov. 14.

The therapy, Kebilidi, was approved to treat adults and children with aromatic L-amino acid decarboxylase deficiency, a rare genetic disorder that affects the body’s ability to produce neurotransmitters that support motor function.

Kebilidi is administered via four infusions into a part of the brain...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Provider
What might a Trump administration mean for the Biosecure Act?
Flagship, Pfizer alliance yields two more startup deals
Wondr Health Expands Weight Loss Program with Support for GLP-1 Users
GeneDx Launches Tool to Fuel Rare Disease Drug Discovery
MedCity Pivot Podcast: Self-insured Employers Weigh Benefits of GLP-1 Drugs

Share This Article